Raymond James lowered the firm’s price target on Haemonetics (HAE) to $105 from $115 and keeps a Strong Buy rating on the shares. The Q4 print was in line on revenues and slightly ahead on EPS due to below-the-line dynamics, the analyst tells investors in a research note. The guidance for fiscal 2026 is in line to better than hopes even net of a tariff headwind and could still prove conservative, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Reports Mixed Fiscal 2025 Results
- Haemonetics participates in a conference call with JPMorgan
- Haemonetics: Buy Rating Affirmed Amid Strong Q4 Performance and Margin Improvements
- Haemonetics Approves Strategic Alignment Initiative in May 2025
- Haemonetics sees FY26 adjusted EPS $4.70-$5.00, consensus $4.93